Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

To evaluate the effects of continuous infusion of methylene blue (MB), an inhibitor of the nitric oxide pathway, on hemodynamics and organ functions in human septic shock.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Twenty patients with septic shock diagnosed <24 hrs before randomization.

Patients were randomized 1:1 to receive either MB (MB group, n = 10) or isotonic saline (control group, n = 10), adjunctive to conventional treatment.

How the Study Was Run

In design terms this was a randomized, open-label and pilot study.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Being open-label, the Methylene blue (non-peptide stack partner) study did not mask who received what.

It is described as a pilot, a small early test of whether a larger Methylene blue (non-peptide stack partner) study would be practical.

Prospective, randomized, controlled, open-label, pilot study.

Multidisciplinary intensive care unit of a university hospital.

What Was Measured

The subject headings attached to it are Blood Chemical Analysis, Chemotherapy, Adjuvant, Hemodynamics, Hospitals, University, Intensive Care Units, Methylene Blue and Pilot Projects.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Methylene blue (non-peptide stack partner).

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (Critical care medicine), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page.